The pharmaceutical company expects the drug Baxfendy to generate multibillion-dollar annual sales at its peak.

By Bhanvi Satija LONDON, May 18 (Reuters) - Anglo-Swedish drugmaker AstraZeneca said on Monday its hypertension pill ...

References: 1.  Mengxia Fu, et al. The Breast, Volume 79, 2025. 2.  Chiu, Chao-Hua et al. eClinicalMedicine, Volume 74, 10270 3.  Yang, C., et al. (2025).

US FDA approves AstraZeneca and Daiichi Sankyo’s Enhertu for two new indications for patients with HER2-positive early breast cancer: Cambridge, UK Monday, May 18, 2026, 10:00 H ...

May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

(Reuters) -AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people ...

Costco, Coca-Cola and AstraZeneca lead Zacks' top stock reports as strong earnings, growth drivers and pipeline momentum lift ...